Next Generation News and Research

RSS

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020

Synthetic riboregulators detect SARS-CoV-2 genome parts in 40 minutes

By exploiting the tools of synthetic biology, the researchers from Turkey have successfully developed a de novo riboregulator system for rapidly detecting the presence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic material. Their paper is currently available on medRxiv preprint server.

2 Aug 2020

NIH invests $248.7 million in new COVID-19 testing technologies to meet U.S. demand

The National Institutes of Health is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus).

31 Jul 2020

Harbour BioMed and Viva Biotech announce strategic collaboration to promote incubation of biotech startups

Harbour BioMed, a global clinical stage biopharmaceutical company and Viva Biotech (Shanghai) Ltd., a world-leading structure-based drug discovery platform today announced a strategic partnership under which both parties will collate their respective expertise in drug discovery and development to promote the incubation of innovative biotech startups.

31 Jul 2020

Compounds demonstrate promising activity against tuberculosis

Compounds tested for their potential as antibiotics have demonstrated promising activity against one of the deadliest infectious diseases - tuberculosis (TB).

30 Jul 2020

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.

29 Jul 2020

OU physician receives $1.6 million NIH grant for knee osteoarthritis research

By the time they turn 65, at least half of people suffer from osteoarthritis, a condition that impairs quality of life and cannot be slowed by medication.

28 Jul 2020

Brigham to play two key roles in phase 3 trial of COVID-19 vaccine candidate

A vaccine candidate for preventing COVID-19 is advancing to a 30,000-participant phase 3 trial that begins today, and Brigham and Women's Hospital will play two key roles in the trial's next phase.

27 Jul 2020

Researchers use new approach to unravel the mechanisms that lie behind tetraploidy

Cell division is a fundamental process that organisms need to reproduce, grow, and make repairs. But when an error disrupts this complex biological process, cellular abnormalities can lead to diseases, such as cancer, where cells are enabled to grow and divide out of control.

25 Jul 2020

SMCSE hosts National Symposium on Developing Socially Responsible STEM Professionals

On January 14th 2020, City's School of Mathematics, Computer Science and Engineering (SMCSE) hosted its first National Symposium on Developing Socially Responsible STEM Professionals.

25 Jul 2020

Sputum testing detects COVID-19 virus at higher rates than other methods

Early and accurate detection is critical for preventing the spread of COVID-19 and providing appropriate care for patients.

24 Jul 2020

Olympus and Cytosurge collaborate to deliver a complete single-cell and CRISPR genetic manipulation solution in the Americas

Olympus, a leading manufacturer of high-end research microscopes, and Cytosurge, a precision manufacturer of cell manipulation technologies, have entered a co-marketing agreement to become a complete system provider to the scientific community’s growing need for next-generation single-cell and CRISPR genetic manipulation solutions.

From Evident Corporation - Life Sciences 24 Jul 2020

Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery

Biognosys announced today that it started working together with Boehringer Ingelheim.

From Biognosys 24 Jul 2020

Researchers design new version of protein to develop COVID-19 vaccine

Responding to a need to quickly develop billions of doses of lifesaving COVID-19 vaccines, a scientific team at The University of Texas at Austin has successfully redesigned a key protein from the coronavirus, and the modification could enable much faster and more stable production of vaccines worldwide.

24 Jul 2020

New model may explain why certain cancer cells are resistant to therapy

Cancer's knack for developing resistance to chemotherapy has long been a major obstacle to achieving lasting remissions or cures.

24 Jul 2020

Mouse orthotopic model was used to determine personalized therapy for relapse sarcoma

A team from IDIBELL and ICO, using a mouse orthotopic model, conducted a real-time personalized oncology study to test the best therapeutic option to treat a type of relapse sarcoma. Malignant Peripheral Nerve Sheath Tumor are very aggressive and do not usually have a good prognosis, especially if complete surgical excision cannot be achieved.

23 Jul 2020

Doctors and data scientists call on hospitals to become 'AI ready'

A group of doctors and data scientists is calling on hospitals to create clinical departments devoted to artificial intelligence to harness the power of the technology to transform patient care.

23 Jul 2020

Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing.

23 Jul 2020

Study identifies common characteristics of pediatric vestibular schwannomas

Vestibular schwannomas, more commonly known as acoustic neuromas, are benign brain tumors that develop on the balance (vestibular) and hearing or auditory nerves leading from the inner ear to the brain.

23 Jul 2020

Vesigen Therapeutics to develop and commercialize novel drug-delivery technologies

Harvard University's Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest.

23 Jul 2020

Next Generation News and Research

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

Synthetic riboregulators detect SARS-CoV-2 genome parts in 40 minutes

NIH invests $248.7 million in new COVID-19 testing technologies to meet U.S. demand

Harbour BioMed and Viva Biotech announce strategic collaboration to promote incubation of biotech startups

Compounds demonstrate promising activity against tuberculosis

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

OU physician receives $1.6 million NIH grant for knee osteoarthritis research

Brigham to play two key roles in phase 3 trial of COVID-19 vaccine candidate

Researchers use new approach to unravel the mechanisms that lie behind tetraploidy

SMCSE hosts National Symposium on Developing Socially Responsible STEM Professionals

Sputum testing detects COVID-19 virus at higher rates than other methods

Olympus and Cytosurge collaborate to deliver a complete single-cell and CRISPR genetic manipulation solution in the Americas

Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery

Researchers design new version of protein to develop COVID-19 vaccine

New model may explain why certain cancer cells are resistant to therapy

Mouse orthotopic model was used to determine personalized therapy for relapse sarcoma

Doctors and data scientists call on hospitals to become 'AI ready'

Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

Study identifies common characteristics of pediatric vestibular schwannomas

Vesigen Therapeutics to develop and commercialize novel drug-delivery technologies

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News